Cancer Rop Co. Ltd. Total Liabilities

Latest as of March 2026: ₩24.60 Billion KRW ≈ $16.67 Million USD

Cancer Rop Co. Ltd. total liabilities. Based on the latest financial reports, Cancer Rop Co. Ltd. (180400) has total liabilities worth ₩24.60 Billion KRW (≈ $16.67 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See 180400 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Total Liabilities of Cancer Rop Co. Ltd. (2014–2025)

Total liabilities of Cancer Rop Co. Ltd. from 2014 to 2025. This chart illustrates how Cancer Rop Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Cancer Rop Co. Ltd. to evaluate the company's liquid asset resilience ratio.

Cancer Rop Co. Ltd. Competitors by Total Liabilities

The table below lists competitors of Cancer Rop Co. Ltd. ranked by their total liabilities.

Company Country Total Liabilities
Severn Trent PLC
LSE:SVT
UK GBX15.73 Billion
Thai Steel Cable Public Company Limited
BK:TSC
Thailand ฿563.82 Million
Caisse Regionale De Credit Agricole Mutuel Sud Rhone Alpes
PA:CRSU
France €24.15 Billion
STLLR Gold Inc.
TO:STLR
Canada CA$8.05 Million
Atlas Salt Inc
V:SALT
Canada CA$2.57 Million
RumbleON Inc
NASDAQ:RMBL
USA $717.00 Million
John Hancock Income Securities Closed Fund
NYSE:JHS
USA $93.25 Million
Joyce Corporation Ltd
AU:JYC
Australia AU$57.55 Million

Liability Composition Analysis (2014–2025)

This chart breaks down Cancer Rop Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 180400 asset base.

Liquidity & Leverage Metrics

Cancer Rop Co. Ltd. Total Liabilities Ratios Explained

Cancer Rop Co. Ltd. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 5.08 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.28 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.21 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Cancer Rop Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Cancer Rop Co. Ltd. (2014–2025)

The table below shows the annual total liabilities of Cancer Rop Co. Ltd. from 2014 to 2025.

Year Total Liabilities Change
2025-12-31 ₩59.11 Billion
≈ $40.06 Million
+5.54%
2024-12-31 ₩56.00 Billion
≈ $37.95 Million
-21.28%
2023-12-31 ₩71.14 Billion
≈ $48.21 Million
+37.87%
2022-12-31 ₩51.60 Billion
≈ $34.97 Million
+58.10%
2018-12-31 ₩32.64 Billion
≈ $22.12 Million
+45.15%
2017-12-31 ₩22.49 Billion
≈ $15.24 Million
+3388.71%
2016-12-31 ₩644.52 Million
≈ $436.78K
+4.83%
2015-12-31 ₩614.80 Million
≈ $416.64K
+17.58%
2014-12-31 ₩522.87 Million
≈ $354.34K
--

About Cancer Rop Co. Ltd.

KQ:180400 Korea Diagnostics & Research
Market Cap
$121.40 Million
₩179.14 Billion KRW
Market Cap Rank
#18275 Global
#799 in Korea
Share Price
₩1820.00
Change (1 day)
-3.60%
52-Week Range
₩1820.00 - ₩2760.00
All Time High
₩2760.00
About

Dx & Vx Co., Ltd. engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea. The company offers healthcare products, including Ofmom Carefree, oat fermented food, and biocleaners; diagnostic products, comprising CLIDEX, precision diagnostics, and in vitro diagnostic kit; health check services; CDx development services;… Read more